Cargando…
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
INTRODUCTION: There are few effective treatment options for leptomeningeal metastasis (LM) in non-small-cell lung cancer (NSCLC). This study assessed the feasibility of high-dose gefitinib in patients with LM from NSCLC harboring EGFR mutations or prior systemic response to EGFR-TKI. METHODS: This p...
Autores principales: | Jackman, David M., Cioffredi, Leigh A., Jacobs, Lorraine, Sharmeen, Farhana, Morse, Linda K., Lucca, Joan, Plotkin, Scott R., Marcoux, Paul J., Rabin, Michael S., Lynch, Thomas J., Johnson, Bruce E., Kesari, Santosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414209/ https://www.ncbi.nlm.nih.gov/pubmed/25784657 |
Ejemplares similares
-
Leptomeningeal metastasis in breast cancer – a systematic review
por: Scott, Brian J., et al.
Publicado: (2015) -
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012) -
Ovarian Adenocarcinoma With Leptomeningeal Metastases
por: Bayas, Angel, et al.
Publicado: (2022) -
Helical tomotherapy in patients with leptomeningeal metastases
por: Schiopu, Sanziana RI, et al.
Publicado: (2018) -
Diffuse cerebellar hypermetabolism: an early sign of leptomeningeal metastases
por: Broen, M. P. G., et al.
Publicado: (2021)